Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.
Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paridaens R, et al. J Clin Oncol. 2000 Feb;18(4):724-33. doi: 10.1200/JCO.2000.18.4.724. J Clin Oncol. 2000. PMID: 10673513 Clinical Trial.
An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
Piccart MJ, Bruning P, Wildiers J, Awada A, Schornagel JH, Thomas J, Tomiak E, Bartholomeus S, Witteveen PO, Paridaens R. Piccart MJ, et al. Among authors: paridaens r. Ann Oncol. 1995 Sep;6(7):673-7. doi: 10.1093/oxfordjournals.annonc.a059283. Ann Oncol. 1995. PMID: 8664188 Free article. Clinical Trial.
Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Piccart MJ, et al. Among authors: paridaens r. J Clin Oncol. 1997 Sep;15(9):3149-55. doi: 10.1200/JCO.1997.15.9.3149. J Clin Oncol. 1997. PMID: 9294478 Clinical Trial.
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group.
Paridaens R, Roy JA, Nooij M, Klijn J, Houston SJ, Beex LV, Vinholes J, Tomiak E, Van Vreckem A, Langenaeken C, Van Glabbeke M, Piccart MJ. Paridaens R, et al. Anticancer Drugs. 1998 Jan;9(1):29-35. doi: 10.1097/00001813-199801000-00003. Anticancer Drugs. 1998. PMID: 9491789 Clinical Trial.
A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
Hamilton A, Larsimont D, Paridaens R, Drijkoningen M, van de Vijver M, Bruning P, Hanby A, Houston S, Treilleux I, Guastalla JP, Van Vreckem A, Sylvester R, Piccart M. Hamilton A, et al. Among authors: paridaens r. Clin Breast Cancer. 2000 Oct;1(3):233-40; discussion 241-2. doi: 10.3816/CBC.2000.n.020. Clin Breast Cancer. 2000. PMID: 11899648 Clinical Trial.
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M; European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC). Paridaens R, et al. Ann Oncol. 2003 Sep;14(9):1391-8. doi: 10.1093/annonc/mdg362. Ann Oncol. 2003. PMID: 12954578 Free article. Clinical Trial.
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R, Rotmensz N, Sylvester R, Mouridsen HT, Klijn JG, van Oosterom AT. Bontenbal M, et al. Among authors: paridaens r. Br J Cancer. 1998 Jun;77(12):2257-63. doi: 10.1038/bjc.1998.375. Br J Cancer. 1998. PMID: 9649142 Free PMC article. Clinical Trial.
273 results